SCHEMBL16185095

SCHEMBL16185095

CCCCOc1cc(-c2ccc(F)c(F)c2)cc2c(NC)nc(-c3cccnc3)nc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 3/20 0.43
▸ CYP2D6 P10635 3/20 0.43
▸ CYP2C9 P11712 3/20 0.43
▸ CYP2C19 P33261 3/20 0.43
▸ CYP1A2 P05177 2/20 0.43
▸ HSD17B10 Q99714 2/20 0.43
▸ CLK4 Q9HAZ1 2/20 0.43
▸ MAPT P10636 3/20 0.41
▸ HTT P42858 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ NPC1 O15118 2/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ CYP19A1 P11511 2/20 0.41
▸ CHRNB2 P17787 1/20 0.40
▸ CHRNA5 P30532 1/20 0.40
▸ CHRNA4 P43681 1/20 0.40
▸ GBA1 P04062 4/20 0.39
▸ CYP11B1 P15538 1/20 0.39
▸ CYP11B2 P19099 1/20 0.39
▸ MKNK1 Q9BUB5 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16185094 0.95 CYP1A2 (0.43) CYP3A4CYP2D6CYP2C9CYP2C19CYP1A2
SCHEMBL16185099 0.92 CYP1A2 (0.42) CYP3A4CYP2D6CYP2C9CYP2C19CYP1A2
SCHEMBL16185096 0.92 CYP1A2 (0.43) CYP3A4CYP2D6CYP2C9CYP2C19CYP1A2
SCHEMBL16184851 0.92 HSD17B10 (0.45) CYP3A4CYP2D6CYP2C9CYP2C19CYP1A2
SCHEMBL16184956 0.92 CYP3A4 (0.46) CYP3A4CYP2D6CYP2C9CYP2C19CYP1A2
SCHEMBL16185098 0.91 CYP1A2 (0.43) CYP3A4CYP2D6CYP2C9CYP2C19CYP1A2
SCHEMBL16185110 0.91 CYP1A2 (0.41) CYP3A4CYP2D6CYP2C9CYP2C19CYP1A2
SCHEMBL16184928 0.90 ABCG2 (0.44) CYP3A4CYP2D6CYP2C9CYP2C19CYP1A2
SCHEMBL16185066 0.90 CYP3A4 (0.45) CYP3A4CYP2D6CYP2C9CYP2C19CYP1A2
SCHEMBL16185101 0.89 CYP1A2 (0.41) CYP3A4CYP2D6CYP2C9CYP2C19CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB CYP3A4 4456/4885CYP2D6 4357/4885CYP2C9 4632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback